Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03629847
Other study ID # 2121-159
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date December 2012
Est. completion date December 2018

Study information

Verified date August 2018
Source King Faisal Specialist Hospital & Research Center
Contact Ali Aljubran, MD
Phone 966-11-4647272
Email ajubran@kfshrc.edu.sa
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

NET originate in neuroendocrine cells throughout the body. The goal of this study is to assess the safety and efficacy of the combination of everolimus and the intravenous radiolabeled Lu-177 DOTATATE Therapy as a 1st line therapy in unresectable well to moderately differentiated metastatic neuroendocrine tumors of all GI, lung and pancreatic origins. This is a phase 1 - 2 study. The phase 1 part involves finding the maximum tolerating dose (MTD) of Everolimus.


Description:

Neuroendocrine tumors NET refers to tumors that originate in neuroendocrine cells throughout the body (including in the thymus, lung, pancreas, gastrointestinal [GI] tract and less common sites). They can be broadly subclassified into well-differentiated and poorly differentiated cancers. Treatment of well differentiated NET are complex and involves surgical, Locoregional and systemic modalities depending on the manifestations as well as extent of disease. Treatment is best planned in a multidisciplinary tumor board. Of the emerging new systemic modalities are Everolimus and radiolabelled somatostatin analogue. The goal of this study is to assess the safety and efficacy of the combination of everolimus and the intravenous radiolabeled Lu-177 DOTATATE Therapy (a somatostatin analogue) as a first line therapy in unresectable well to moderately differentiated metastatic neuroendocrine tumors of all gastrointestinal, lung and pancreatic origins. This is a phase 1 - 2 study. The phase 1 part involves finding the maximum tolerating dose (MTD) of Everolimus.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 2018
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Age > 18 years old.

- Histologically confirmed well to moderately differentiated neuroendocrine tumors of GI, lung or pancreatic origin. The grading follows the WHO grading system (Appendix III).

- Measurable disease by CT or MRI.

- Positive Tc-99m Octreotide scan or Ga-68 Octreotate scan (Positive means uptake at tumor sites).

- Advanced disease which are not treatable by surgical resection.

- Documented progressive disease within the past 12 months.

- WHO Performance Status 0 - 2.

- Fasting blood sugar = 1.5 ? Upper Limit of Normal (ULN).

- Fasting triglycerides = 2.5 ? Upper Limit of Normal (ULN), and fasting cholesterol = 300 mg/dl or = 7.75 ml/l.

- Adequate renal function with creatinine clearance = 60 ml/l.

- Adequate hepatic function:

- Total bilirubin = 1.5 ? Upper Limit of Normal (ULN)

- Liver Function Tests (Serum aspartate aminotransferase and alanine transaminase levels) = 2.5 ? ULN (and = 5 ? ULN, in case of presence of liver metastasis)

- Adequate hematological values:

- Absolute neutrophil count = 1 x 109/L

- Platelet count = 100 x 109/L

- Signed written informed consent before enrolment.

Exclusion Criteria:

- Readily completely Resectable disease.

- Prior therapy with everolimus or systemic chemotherapy.

- Prior chemoembolization, radio-embolization, or bland embolization within 6 months before enrolment. Likewise, patients are ineligible if had undergone conventional radiotherapy, radiofrequency ablation, cryoablation or alcohol injection within 1 month prior to enrolment.

- Prior long acting somatostatin analogue within 1 month prior to enrolment. Short acting somatostatin analogue is allowed as long as it is not administered within 12 hours before or /and 12 hours after the administration of the intravenous radiolabelled Lu-177 DOTATATE Therapy.

- Presence of Central Nervous System metastasis.

- Previous malignancy within 5 years, except adequately treated non melanomatous skin cancer or in situ cervical cancer

- Other active malignancy.

- HIV infection.

- Severe or uncontrolled medical conditions, such as:

- Active uncontrolled severe infection

- History of invasive fungal infection.

- Child C liver dysfunction.

- Severely impaired lung function.

- Psychiatric or mental disorder, precluding understanding of the information of the trial related topics and giving valid informed consent.

- Any psychological, familial, geographic or social circumstances which could impair the patient's ability to participate in the trial and comply with follow up.

- Treatment with other anti-cancer therapy.

- Known hypersensitivity to any of the study drugs.

- Pregnant or breast feeding women.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Everolimus
Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.

Locations

Country Name City State
Saudi Arabia Oncology Centre, King Faisal Specialist Hospital & Research Center Riyadh

Sponsors (1)

Lead Sponsor Collaborator
King Faisal Specialist Hospital & Research Center

Country where clinical trial is conducted

Saudi Arabia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of treatment related adverse events Establish safety profile of the combination of everolimus and intravenous radiolabeled Lu-177 DOTATATE "3 years"
Secondary Survival assessment Progression free survival (PFS) and Overall survival (OS) 3 years
See also
  Status Clinical Trial Phase
Completed NCT01218555 - Study of Everolimus (RAD001) in Combination With Lenalidomide Phase 1
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Withdrawn NCT04614766 - A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors Phase 1/Phase 2
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Completed NCT03273712 - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) Phase 2
Recruiting NCT05636618 - Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors Phase 1/Phase 2
Terminated NCT03986593 - Cryoablation of Bone Metastases From Endocrine Tumors N/A
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Completed NCT02815969 - The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors
Completed NCT02441062 - Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors Phase 2
Active, not recruiting NCT02174549 - Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer Phase 1/Phase 2
Completed NCT02132468 - A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers Phase 2
Completed NCT02134639 - PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation N/A
Recruiting NCT01201096 - Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE) N/A
Terminated NCT01163526 - Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies N/A
Completed NCT01099228 - Combination Targeted Radiotherapy in Neuroendocrine Tumors N/A
Completed NCT00171873 - Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut Phase 3
Active, not recruiting NCT05077384 - Open-label Study of Surufatinib in Japanese Patients Phase 1/Phase 2
Active, not recruiting NCT04544098 - Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver Early Phase 1
Active, not recruiting NCT02736500 - Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors Phase 1/Phase 2